» Articles » PMID: 36302039

Polypharmacy and Medical Intensive Care Unit (MICU) Admission and 10-year All-cause Mortality Risk Among Hospitalized Patients with and Without HIV

Overview
Journal PLoS One
Date 2022 Oct 27
PMID 36302039
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Medical intensive care unit (MICU) admissions have been declining in people with HIV infection (PWH), but frequency of outpatient polypharmacy (prescription of ≥5 chronic medications) has increased. Among those hospitalized, we examined whether outpatient polypharmacy is associated with subsequent 1-year MICU admission or 10-year all-cause mortality, and if the association varies by HIV status.

Design: Retrospective cohort study.

Methods: Using a national electronic health record cohort of Veterans in care, we ascertained outpatient polypharmacy during fiscal year (FY) 2009 and followed patients for 1-year MICU admission and 10-year mortality. We assessed associations of any polypharmacy (yes/no and categorized ≤4, 5-7, 8-9, and ≥10 medications) with 1-year MICU admission and 10-year mortality using logistic and Cox regressions, respectively, adjusted for demographics, HIV status, substance use, and severity of illness.

Results: Among 9898 patients (1811 PWH) hospitalized in FY2010, prior outpatient polypharmacy was common (51%). Within 1 year, 1532 (15%) had a MICU admission and within 10 years, 4585 (46%) died. Polypharmacy was associated with increased odds of 1-year MICU admission, in both unadjusted (odds ratio (OR) 1.36 95% CI: (1.22, 1.52)) and adjusted models, aOR (95% CI) = 1.28 (1.14, 1.43) and with 10-year mortality in unadjusted, hazard ratio (HR) (95% CI) = 1.40 (1.32, 1.48), and adjusted models, HR (95% CI) = 1.26 (1.19, 1.34). Increasing levels of polypharmacy demonstrated a dose-response with both outcomes and by HIV status, with a stronger association among PWH.

Conclusions: Among hospitalized patients, prior outpatient polypharmacy was associated with 1-year MICU admission and 10-year all-cause mortality after adjusting for severity of illness in PWH and PWoH.

Citing Articles

The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol.

Womack J, Leblanc M, Sager A, Zaets L, Maisto S, Garcia A AIDS Behav. 2024; 29(2):482-496.

PMID: 39465468 DOI: 10.1007/s10461-024-04533-6.


Polypharmacy and Aging in People Living with HIV: 6 Years of Experience in a Multidisciplinary Outpatient Clinic.

Cattaneo D, Oreni L, Meraviglia P, Minisci D, Astuti N, Antinori S Drugs Aging. 2023; 40(7):665-674.

PMID: 37310576 DOI: 10.1007/s40266-023-01037-1.

References
1.
Cho H, Chae J, Yoon S, Kim D . Aging and the Prevalence of Polypharmacy and Hyper-Polypharmacy Among Older Adults in South Korea: A National Retrospective Study During 2010-2019. Front Pharmacol. 2022; 13:866318. PMC: 9124766. DOI: 10.3389/fphar.2022.866318. View

2.
Rockwood K, Noseworthy T, Gibney R, Konopad E, Shustack A, Stollery D . One-year outcome of elderly and young patients admitted to intensive care units. Crit Care Med. 1993; 21(5):687-91. DOI: 10.1097/00003246-199305000-00011. View

3.
Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, McAllister K, Bellon J, Gibbons S . Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. Clin Infect Dis. 2019; 71(2):353-362. DOI: 10.1093/cid/ciz811. View

4.
Payne R, Avery A, Duerden M, Saunders C, Simpson C, Abel G . Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014; 70(5):575-81. DOI: 10.1007/s00228-013-1639-9. View

5.
Tate J, Justice A, Hughes M, Bonnet F, Reiss P, Mocroft A . An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2012; 27(4):563-72. PMC: 4283204. DOI: 10.1097/QAD.0b013e32835b8c7f. View